Published: Vol 6, Iss 1, Jan 5, 2016 DOI: 10.21769/BioProtoc.1696 Views: 8926
Reviewed by: HongLok LungClara Lubeseder-MartellatoAnonymous reviewer(s)
Protocol Collections
Comprehensive collections of detailed, peer-reviewed protocols focusing on specific topics
Related protocols
Measuring Protein Synthesis during Cell Cycle by Azidohomoalanine (AHA) Labeling and Flow Cytometric Analysis
Koshi Imami and Tomoharu Yasuda
Apr 20, 2019 8796 Views
Analysis of the Ubiquitination and Phosphorylation of Vangl Proteins
Di Feng [...] Bo Gao
Oct 20, 2022 2588 Views
Isoform-specific, Semi-quantitative Determination of Highly Homologous Protein Levels via CRISPR-Cas9-mediated HiBiT Tagging
Kristina Seiler [...] Mario P. Tschan
Jul 20, 2023 1552 Views
Abstract
Galectin-3 is a member of a class of proteins termed Galectins, characterized by their ability to bind glycans containing β-galactose (Cummings and Liu, 2009). Galectin-3 binds preferentially to proteoglycans terminating with N-acetyllactosamine (LacNAc) chains (i.e., tandem repeats of galactose) (Newlaczyl and Yu, 2011). Galectin-3 is unique among the galectins in its chimeric structure. It shares a conserved carbohydrate recognition domain (CRD) with the other galectins, but has a long amino-terminal tail that is thought to be involved in protein aggregation. It can also form homodimers through its CRD (Cummings and Liu, 2009). Galectin-3 has been found to have diverse functions in tumorigenesis including: signaling, apoptosis inhibition, immune suppression, cell growth, and metastasis among others. Galectin-3 is frequently upregulated in cancers (Nangia-Makker et al., 2008). Its function largely depends on its expression and localization properties (Newlaczyl and Yu, 2011). Because of its many roles in cancer-associated processes, establishing a method for Galectin-3 production is valuable for further study of its functions in cancer. Here, we describe how Galectin-3 purification was achieved by cloning of the human Galectin-3 gene into pGEX-2T vector containing the gene for glutathione-S-transferase (GST) upstream of its cloning site. The Galectin-3 gene was cloned into this vector via restriction digests of both the plasmid and the Galectin-3 gene by restriction enzymes BamHI and EcoRI, followed by ligation of the two fragments. The resulting plasmid was then used to transform BL21, an Escherichia coli (E. coli) strain specialized for protein expression. Finally, we discuss how the GST fusion protein was isolated and the recombinant Galectin-3 protein was further purified from the GST.
Keywords: CancerPart I. Protocol for GST-Gal3 purification (Harper and Speicher, 2011)
Materials and Reagents
Equipment
Procedure
Recipes
Part II. Protocol for thrombin-mediated cleavage of GST from GST-Gal3
Materials and Reagents
Equipment
Procedure
Recipes
Acknowledgments
We thank Dr. William Stallcup (Sanford-Burnham Medical Research Institute; Cancer Center; La Jolla, CA USA) for providing the GST-Gal3 expression plasmids. This work was supported by R01 grant CA163722 from the NIH (to EGVM).
References
Article Information
Copyright
© 2016 The Authors; exclusive licensee Bio-protocol LLC.
How to cite
Tyler, K., Lee, S. and Van Meir, E. G. (2016). Preparation of Recombinant Galectin-3 for Cancer Studies. Bio-protocol 6(1): e1696. DOI: 10.21769/BioProtoc.1696.
Category
Cancer Biology > General technique > Biochemical assays
Cancer Biology > General technique > Tumor microenvironment
Biochemistry > Protein > Expression
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link